Affinage

MORC2

ATPase MORC2 · UniProt Q9Y6X9

Length
1032 aa
Mass
117.8 kDa
Annotated
2026-06-10
75 papers in source corpus 33 papers cited in narrative 33 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 8/8 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

MORC2 is a GHKL-type ATPase that functions as a DNA compaction machine and chromatin remodeler, serving as the essential effector of the HUSH complex to maintain epigenetic silencing of retrotransposons and heterochromatin through H3K9me3 deposition (PMID:28581500, PMID:41414675). Mechanistically, full-length MORC2 binds DNA through C-terminal sites, topologically entrapping DNA substrates between its N-terminal GHKL module and C-terminal coiled-coil dimerization domains, and uses ATP hydrolysis to drive DNA compaction; DNA binding feeds back to modulate ATPase activity and is itself regulated by phosphorylation of the C-terminal region (PMID:39739841, PMID:40593625). Crystallographic and cryo-EM analyses show that ATP-dependent dimerization of the ATPase-CW module, together with biomolecular condensation nucleated through coiled-coil 3 and an intrinsically disordered region, organizes MORC2 into dynamic nuclear assemblies required for transcriptional repression (PMID:29440755, PMID:42160388). In heterochromatin maintenance MORC2 acts within and downstream of a DNA-methylation hierarchy, where retrotransposon promoter methylation and HUSH-MORC2 silencing operate as parallel layers, and MORC2 is preferentially recruited to activated LINE-1 elements (PMID:39214989); in male germ cells it performs stage-dependent silencing of LINE1/IAP retrotransposons and meiotic sex chromosome inactivation in cooperation with MORC1 and SETDB1 (PMID:41414675). MORC2 also participates in the DNA damage response: PAK1 phosphorylates it at S739 to stimulate its DNA-dependent ATPase activity and γ-H2AX induction, and damage-induced homodimerization promotes nucleosome destabilization and recruitment of repair factors (PMID:23260667, PMID:31796101). Its activity is extensively tuned by post-translational modifications — including PARylation by PARP1 within the CW zinc finger, NAT10-mediated acetylation reversed by SIRT2, and SUMOylation at K767 controlled by TRIM28 and SENP1 — that govern its ATPase activity, chromatin remodeling, and protein stability during DNA repair (PMID:32112098, PMID:31616951, PMID:36793866). Beyond canonical silencing, MORC2 acts as a transcriptional co-repressor by recruiting histone deacetylases, EZH2/PRC2, and DNMT3A to target promoters and drives cancer progression in part through alternative-splicing partners hnRNPM and RBM39 (PMID:20110259, PMID:29555977, PMID:30093560, PMID:39048555). The CMT2Z-associated p.Arg252Trp mutation hyperactivates HUSH-mediated silencing, and disease mutations disrupt ATPase dimerization dynamics and condensate properties (PMID:28581500, PMID:29440755, PMID:42160388).

Mechanistic history

Synthesis pass · year-by-year structured walk · 13 steps
  1. 2010 Medium

    Established MORC2 as a sequence-specific transcriptional repressor and defined the C-terminal elements governing its nuclear localization and repressive function.

    Evidence Deletion mutagenesis, ChIP/sequential ChIP, and reporter assays in cancer cells identifying NLS/NES and co-repression with HDAC4 at the CAIX promoter

    PMID:20110259 PMID:20225202

    Open questions at the time
    • No structural basis for DNA/chromatin engagement
    • Genome-wide target spectrum not defined
    • Direct vs. indirect promoter binding unresolved
  2. 2012 High

    Identified MORC2 as a DNA-damage-response factor by showing PAK1 phosphorylation at S739 activates its DNA-dependent ATPase and chromatin remodeling to promote repair.

    Evidence In vitro kinase assay, S739A mutagenesis, chromatin association and DNA-damage sensitivity assays

    PMID:23260667

    Open questions at the time
    • Mechanism linking ATPase activity to repair not resolved
    • Did not define chromatin targets in the damage context
  3. 2017 High

    Defined MORC2's core physiological role as the essential ATPase effector of the HUSH complex that compacts chromatin and enforces H3K9me3-dependent silencing of heterochromatic loci.

    Evidence Genome-wide CRISPR screen, chromatin accessibility (DIVA) assay, H3K9me3 ChIP, ATPase mutant analysis

    PMID:28581500

    Open questions at the time
    • Molecular mechanism of HUSH-directed recruitment not resolved
    • How CMT mutation hyperactivates silencing unexplained at structural level
  4. 2018 High

    Provided the structural basis for MORC2 function, showing ATP-induced dimerization of the GHKL-CW module and DNA binding are required for silencing, and that disease mutations act through distinct dimerization defects.

    Evidence X-ray crystallography of wild-type and mutant fragments with biochemical dimerization, DNA-binding, and cellular silencing assays

    PMID:29440755

    Open questions at the time
    • Used isolated fragments rather than full-length protein
    • How dimerization couples to processive DNA compaction unresolved
  5. 2018 Medium

    Expanded MORC2's co-repressor repertoire by linking it to PRC2/EZH2- and DNMT3A-mediated silencing at specific oncogenic loci.

    Evidence Co-IP, ChIP for EZH2/H3K27me3 and DNMT3A, bisulfite sequencing, and functional assays at ArgBP2, NF2/KIBRA promoters

    PMID:29339121 PMID:29555977

    Open questions at the time
    • Whether recruitment is direct or HUSH-dependent unclear
    • Single-lab loci, not genome-wide
  6. 2019 Medium

    Showed that MORC2 activity and recruitment in DNA repair are controlled by PARP1-mediated PARylation and damage-enhanced C-terminal homodimerization driving nucleosome destabilization.

    Evidence Reciprocal Co-IP, in vitro/in vivo PARylation, ATPase and chromatin remodeling assays, MNase assays, repair-factor recruitment assays

    PMID:31616951 PMID:31796101

    Open questions at the time
    • Reciprocal MORC2-PARP1 stabilization circuit needs orthogonal validation
    • Quantitative contribution to repair pathway choice unclear
  7. 2020 High

    Connected MORC2 acetylation to cell-cycle checkpoint control, showing NAT10/SIRT2-regulated K767 acetylation directs binding to H3T11P and repression of CDK1/Cyclin B1.

    Evidence In vivo/in vitro acetylation assays, K767R mutagenesis, ChIP, cell-cycle and clonogenic survival assays

    PMID:32112098

    Open questions at the time
    • Interplay between K767 acetylation and K767 SUMOylation not reconciled
    • Structural basis of H3T11P recognition unknown
  8. 2023 High

    Resolved a dynamic SUMOylation switch at K767 that times chromatin relaxation and re-compaction during DNA repair and couples MORC2 to CK2/DNA-PKcs signaling.

    Evidence In vitro SUMOylation reconstitution, GST pull-down, MNase chromatin assays, K767R mutagenesis, xenograft models

    PMID:36793866

    Open questions at the time
    • How competing K767 modifications are prioritized in vivo unresolved
    • Direct effect of SUMOylation on ATPase/compaction not measured
  9. 2024 High

    Established the epistatic relationship between DNA methylation and HUSH-MORC2 silencing of LINE-1, showing the two operate as redundant layers and MORC2 is recruited to activated L1s.

    Evidence CRISPR depletion of MORC2/TASOR/DNMT1 in neural progenitors, RNA-seq, MORC2 ChIP-seq, bisulfite sequencing, epistasis analysis

    PMID:39214989

    Open questions at the time
    • Signal attracting MORC2 to demethylated/active L1s not identified
    • Direct readers bridging methylation status and MORC2 unknown
  10. 2025 High

    Reconstituted full-length MORC2 to demonstrate ATP-hydrolysis-dependent DNA compaction via a C-terminal DNA-binding clamp and topological entrapment, with phosphorylation tuning activity.

    Evidence In vitro reconstitution, cryo-EM, ATPase and DNA compaction/topology assays, mutagenesis, phosphorylation-state comparison

    PMID:39739841 PMID:40593625

    Open questions at the time
    • In-cell relevance of topological entrapment not directly tested
    • Which kinase-modified states dominate physiologically unresolved
  11. 2025 High

    Showed MORC2 forms dynamic biomolecular condensates, scaffolded by CC3 and IDR-IBD interactions and nucleated by DNA, that allosterically stimulate ATPase activity and are required for repression.

    Evidence Crystal structure of CC3, live-cell imaging, FRAP, phase separation and ATPase assays, killswitch condensate disruption, rescue in MORC2-KO cells

    PMID:42160388

    Open questions at the time
    • Relationship between condensation and HUSH targeting unclear
    • How disease variants alter material properties mechanistically incomplete
  12. 2025 High

    Defined stage-dependent germline functions of MORC2 in retrotransposon silencing and meiotic sex chromosome inactivation, mediated by H3K9me3 with MORC1 and SETDB1.

    Evidence Embryonic and postnatal germ-cell conditional knockout mice, bisulfite sequencing, H3K9me3 ChIP, Co-IP, RNA-seq, fertility assays

    PMID:41414675

    Open questions at the time
    • How stage specificity is determined molecularly unresolved
    • Relative roles of MORC1 vs SETDB1 partnership undefined
  13. 2026 Medium

    Linked CMT2Z-associated MORC2 mutations to motor neuron pathology through disrupted MORC2-PARP1 interaction and impaired PAR-dependent DNA repair, with pharmacological rescue.

    Evidence iPSC-derived motor neurons carrying MORC2 mutations, Co-IP, PARP1 activity and repair-recruitment assays, neurite morphology, PDD rescue

    PMID:41548771

    Open questions at the time
    • Whether PARP1 axis defect fully explains CMT2Z neurodegeneration unclear
    • Relationship between HUSH hyperactivation and PARP1 loss in disease not integrated

Open questions

Synthesis pass · forward-looking unresolved questions
  • How the diverse post-translational modifications, condensation, ATP-dependent dimerization, and HUSH/methylation hierarchies are integrated into a single regulatory logic governing target selection in different cell types remains unresolved.
  • No unified model reconciling competing K767 modifications
  • Recruitment determinants for distinct genomic targets undefined
  • Direct mechanistic basis for CMT2Z silencing hyperactivation incomplete

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0140110 transcription regulator activity 4 GO:0140657 ATP-dependent activity 4 GO:0016787 hydrolase activity 3 GO:0003677 DNA binding 2 GO:0042393 histone binding 1
Localization
GO:0000228 nuclear chromosome 2 GO:0005634 nucleus 2 GO:0005829 cytosol 1
Pathway
R-HSA-4839726 Chromatin organization 4 R-HSA-73894 DNA Repair 4 R-HSA-74160 Gene expression (Transcription) 4 R-HSA-1640170 Cell Cycle 3
Partners
DNMT3AHNRNPMMORC1NAT10PARP1RBM39SETDB1TRIM28
Complex memberships
HUSH complex

Evidence

Reading pass · 33 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2012 MORC2 is a physiological substrate of PAK1 kinase, which phosphorylates MORC2 at serine 739 following DNA damage. Phosphorylated MORC2 regulates its DNA-dependent ATPase activity to facilitate chromatin remodeling, and promotes γ-H2AX induction in a PAK1 phosphorylation-dependent manner. Cells expressing MORC2-S739A showed reduced DNA repair efficiency and hypersensitivity to DNA-damaging agents. In vitro kinase assay, phospho-specific antibodies, site-directed mutagenesis (S739A), chromatin association assays, DNA damage sensitivity assays Cell reports High 23260667
2017 MORC2 is an essential effector of the HUSH complex required for epigenetic silencing. HUSH recruits MORC2 to target sites in heterochromatin; loss of MORC2 results in chromatin decompaction at these loci, loss of H3K9me3 deposition, and transcriptional derepression. The ATPase activity of MORC2 is critical for HUSH-mediated silencing. The most common CMT-associated mutation (p.Arg252Trp) hyperactivates HUSH-mediated repression in neuronal cells. Genome-wide CRISPR-Cas9 forward genetic screen, differential viral accessibility (DIVA) chromatin accessibility assay, H3K9me3 ChIP, transcriptional reporter assays, ATPase mutant analysis Nature genetics High 28581500
2018 Crystal structures of wild-type and neuropathic forms of the MORC2 GHKL-type ATPase module and CW-type zinc finger were determined. The fragment dimerizes upon binding ATP and contains a hinged coiled-coil insertion absent in other GHKL ATPases. Dimerization and DNA binding of the ATPase module are required for HUSH-dependent silencing. Disease mutations alter dimerization dynamics by distinct structural mechanisms: destabilizing the ATPase-CW module, trapping the ATP lid, or perturbing the dimer interface. X-ray crystallography of wild-type and mutant MORC2 fragments, biochemical dimerization assays, DNA binding assays, cellular silencing assays, mutagenesis Nature communications High 29440755
2020 MORC2 is acetylated by acetyltransferase NAT10 at lysine 767 (K767Ac), and this modification is removed by deacetylase SIRT2 under normal conditions. DNA-damaging agents and ionizing radiation stimulate K767Ac by enhancing MORC2-NAT10 interaction. Acetylated MORC2 binds to histone H3 phosphorylated at threonine 11 (H3T11P) and is required for DNA damage-induced reduction of H3T11P and transcriptional repression of CDK1 and Cyclin B1, contributing to G2 checkpoint activation. Acetylation-defective MORC2 (K767R) causes hypersensitivity to DNA-damaging agents. In vivo and in vitro acetylation assays, Co-immunoprecipitation, site-directed mutagenesis (K767R), ChIP, cell-cycle analysis, clonogenic survival assays Nucleic acids research High 32112098
2019 PARP1 interacts with MORC2 and PARylates it at two residues within its CW-type zinc finger domain following DNA damage. PARP1 recruits MORC2 to DNA damage sites, and MORC2 PARylation stimulates its ATPase and chromatin remodeling activities. MORC2 in turn stabilizes PARP1 by enhancing NAT10-mediated acetylation of PARP1 at K949, blocking its ubiquitination and subsequent degradation by E3 ligase CHFR. Mutation of MORC2 PARylation residues reduces cell survival after DNA damage. Co-immunoprecipitation, in vitro and in vivo PARylation assays, ATPase activity assays, chromatin remodeling assays, ubiquitination assays, site-directed mutagenesis, clonogenic survival assays Nucleic acids research High 31616951
2019 MORC2 forms a homodimer through its C-terminal coiled-coil (CC) domain, a process enhanced in response to DNA damage. MORC2 is required for nucleosome destabilization after DNA damage by loosening histone-DNA interaction. Deletion of the C-terminal CC domain disrupts homodimer formation and impairs the ability to destabilize histone-DNA interaction, compromises recruitment of BRCA1, 53BP1, and Rad51 to damage sites, and decreases cell survival after camptothecin treatment. Co-immunoprecipitation for dimerization, MNase (chromatin accessibility) assays, γH2AX focal formation, DNA repair protein recruitment assays (BRCA1, 53BP1, Rad51), deletion mutagenesis, clonogenic survival Cell communication and signaling : CCS Medium 31796101
2010 MORC2 represses transcription of carbonic anhydrase IX (CAIX) through histone deacetylation. MORC2 and HDAC4 are assembled on the same region of the CAIX promoter simultaneously and MORC2 decreases histone H3 acetylation at the CAIX promoter. The PR4 region of MORC2 is required for its transcriptional repression function. DNA microarray, northern/western blot confirmation, ChIP, ChIP Re-IP (sequential ChIP), TSA treatment, promoter reporter assays, deletion analysis Nucleic acids research Medium 20110259
2010 MORC2 subcellular localization is determined by distinct sequence elements: nuclear localization signal (NLS) maps to amino acids 657-781, nuclear export signal (NES) maps to amino acids 481-657. The NLS predominates over the NES in full-length MORC2, resulting in predominantly nuclear localization. The NLS (aa 657-781) and proline-rich domain in the C-terminus are required for transcriptional repressive function. Transient expression of deletion mutants in gastric cancer cells, fluorescence microscopy, transcriptional reporter assays Anatomical record (Hoboken, N.J. : 2007) Medium 20225202
2013 MORC2 interacts with ATP-citrate lyase (ACLY) in the cytosol and promotes ACLY activation in lipogenic breast cancer cells. MORC2 plays an essential role in lipogenesis and adipogenesis, including differentiation of 3T3-L1 preadipocytic cells. Co-immunoprecipitation, ACLY activity assays, lipogenesis assays, adipogenic differentiation assays (3T3-L1 cells), subcellular fractionation Biochimica et biophysica acta Medium 24286864
2015 MORC2 down-regulates p21 (Waf1/Cip1) by recruiting HDAC1 to the p21 promoter in a p53-independent manner, thereby promoting cell cycle progression in gastric cancer cells. ChIP showing MORC2 and HDAC1 co-occupancy at the p21 promoter, promoter reporter assays, western blot for p21, cell cycle analysis Oncotarget Medium 26098774
2015 PAK1-mediated phosphorylation of MORC2 (at S677 in the gastric cancer context) promotes cell cycle progression and tumorigenicity. Phosphorylation-defective MORC2-S677A attenuates proliferation, while phospho-mimetic MORC2-S677E enhances it. Site-directed mutagenesis (S677A, S677E), cell proliferation assays, in vivo tumor growth assays, correlation with PAK1 expression in clinical samples Oncotarget Medium 25888627
2015 MORC2 represses ArgBP2 transcription by enhancing recruitment of EZH2 to the ArgBP2 promoter, promoting H3K27 trimethylation and thereby silencing ArgBP2 expression. ChIP for MORC2 at ArgBP2 promoter, ChIP for H3K27me3, EZH2 recruitment assays, promoter reporter assays, expression knockdown Biochemical and biophysical research communications Medium 26476214
2017 MORC2 promotes breast cancer invasion and metastasis through a proline-rich domain (PRD, residues 601-734) that mediates interaction with catenin delta 1 (CTNND1). Deletion of the PRD domain or knockdown of CTNND1 suppresses MORC2-mediated migration, invasion, and lung metastasis. Proteomic analysis (MS), Co-immunoprecipitation, deletion mutagenesis (PRD), migration/invasion assays, lung colonization in vivo assays, shRNA knockdown Oncotarget Medium 29228664
2018 The cancer-associated MORC2 M276I mutation enhances binding to hnRNPM, a spliceosome component, promoting an hnRNPM-mediated splicing switch of CD44 pre-mRNA from the epithelial isoform (CD44v) to the mesenchymal isoform (CD44s), driving EMT and lung metastasis. Knockdown of hnRNPM reversed the mutant MORC2-induced CD44 splicing switch and EMT. Co-immunoprecipitation, RNA immunoprecipitation (RIP) for CD44 pre-mRNA binding, alternative splicing RT-PCR, migration/invasion/metastasis assays, hnRNPM knockdown rescue experiments Cancer research Medium 30093560
2018 MORC2 forms a complex with DNMT3A at the promoters of NF2 and KIBRA, leading to DNA hypermethylation and transcriptional repression of these Hippo pathway regulators. This suppresses Hippo signaling and promotes hepatocellular carcinoma cell stemness. Co-immunoprecipitation, ChIP for MORC2 and DNMT3A at NF2/KIBRA promoters, bisulfite sequencing for DNA methylation, luciferase promoter assays, knockdown functional assays Cell death and differentiation Medium 29555977
2018 HSF1 directly interacts with MORC2 and this complex binds the ArgBP2 enhancer. HSF1 and MORC2 together increase recruitment of PRC2 (especially EZH2) to the ArgBP2 enhancer, catalyzing H3K27me3 and causing transcriptional repression of ArgBP2, promoting gastric cancer cell migration and invasion. Co-immunoprecipitation (HSF1-MORC2), ChIP for HSF1, MORC2, EZH2, and H3K27me3 at ArgBP2 enhancer, knockdown functional assays Biochimica et biophysica acta. Molecular basis of disease Medium 29339121
2018 MORC2 interacts with SIRT1 and recruits it to the NDRG1 promoter, reducing histone H3 and H4 acetylation (H3Ac, H4Ac) at this locus and suppressing NDRG1 transcription, thereby promoting colorectal cancer cell migration and metastasis. Co-immunoprecipitation (MORC2-SIRT1), ChIP for H3Ac and H4Ac at NDRG1 promoter, MORC2 binding to NDRG1 promoter (-446 to -213 bp) by ChIP, functional migration/metastasis assays Cancer science Medium 30407715
2019 MORC2 is stabilized by estrogen, tamoxifen, and fulvestrant through a GPER1-dependent pathway. GPER1 activates PRKACA, which phosphorylates MORC2 at threonine 582 (T582). Phosphorylated MORC2 shows decreased interaction with HSPA8 and LAMP2A (CMA machinery components), protecting MORC2 from chaperone-mediated autophagy (CMA)-mediated lysosomal degradation. MORC2-T582A mutant fails to restore antiestrogen resistance. Co-immunoprecipitation, site-directed mutagenesis (T582A), phospho-specific antibodies, lysosomal degradation inhibition assays, CMA assays, cell proliferation assays, antiestrogen resistance assays Autophagy Medium 32401166
2019 MORC2 interacts with C/EBPα through its TE-III domain. Overexpression of MORC2 promotes sumoylation of wild-type C/EBPα and its subsequent degradation, but not C/EBPα-K161R mutant. This suppresses C/EBPα-mediated cell differentiation and maintains cell cycle progression. Co-immunoprecipitation, sumoylation assays, site-directed mutagenesis (K161R), differentiation assays (C2C12 cells), cell cycle analysis Cell death and differentiation Medium 30644437
2022 MORC2 is O-GlcNAcylated by OGT at threonine 556. Mutation of this site (T556A) or pharmacological OGT inhibition impairs MORC2-mediated breast cancer cell migration, invasion, and lung colonization. TGF-β1 induces MORC2 O-GlcNAcylation by enhancing GFAT stability (rate-limiting enzyme for sugar donor production). O-GlcNAcylated MORC2 is required for transcriptional activation of TGF-β1 target genes CTGF and SNAIL. In vivo O-GlcNAcylation assays, OGT knockdown and pharmacological inhibition, site-directed mutagenesis (T556A), migration/invasion/metastasis assays, gene expression analysis, GFAT stability assays Cell death and differentiation Medium 34974534
2023 MORC2 is SUMOylated by SUMO1 and SUMO2/3 at lysine 767 (K767) in a SUMO-interacting motif (SIM)-dependent manner. SUMOylation is induced by TRIM28 (E3 ligase) and reversed by SENP1 (deSUMOylase). DNA damage decreases MORC2 SUMOylation (by reducing MORC2-TRIM28 interaction), causing transient chromatin relaxation for DNA repair. At later stages after damage, MORC2 SUMOylation is restored; SUMOylated MORC2 interacts with casein kinase II (CSK21/CK2), which phosphorylates DNA-PKcs to promote DNA repair. In vivo and in vitro SUMOylation assays, Co-immunoprecipitation, GST pull-down, MNase chromatin accessibility assays, chromatin segregation assays, site-directed mutagenesis (K767R), clonogenic survival assays, xenograft models Theranostics High 36793866
2024 MORC2 contains a C-terminal DNA binding site required for gene silencing in cells. DNA binding by MORC2 reduces its ATPase activity, and MORC2 can topologically entrap multiple DNA substrates between its N-terminal GHKL and C-terminal coiled coil 3 (CC3) dimerization domains. Phosphorylation of the C-terminal region modulates DNA binding. Deletion or mutation of the C-terminal DNA-binding region abolishes MORC2-mediated gene silencing. Biochemical DNA binding assays, ATPase activity assays with DNA substrates, DNA topology/entrapment assays, mutagenesis, cellular gene silencing assays, phosphorylation analysis Nucleic acids research High 39739841
2025 Full-length MORC2 mediates ATP hydrolysis-dependent DNA compaction in vitro. MORC2 possesses multiple DNA-binding sites and uses its C-terminal domain (CTD) as a clamp to lock onto DNA. A conserved phosphate-interacting motif within the CTD regulates ATP hydrolysis rate and cooperative DNA binding. CTD phosphorylation state regulates chromatin remodeling activity. Phosphorylated MORC2 shows altered DNA compaction activity compared to unphosphorylated forms. In vitro reconstitution with full-length MORC2, cryo-EM structural analysis, ATPase activity assays, DNA compaction assays, site-directed mutagenesis of phosphate-interacting motif, phosphorylation-state comparison Nature communications High 40593625
2025 MORC2 plays stage-dependent dual roles in male germ cells: retrotransposon (LINE1, IAP) silencing in pre-meiotic germ cells and meiotic sex chromosome inactivation (MSCI) in meiotic cells. Embryonic germ cell-specific MORC2 loss causes LINE1/IAP hypomethylation, meiotic arrest, and male sterility. Postnatal pre-meiotic MORC2 loss causes MSCI failure. Mechanistically, MORC2 represses transcription of sex chromosome-linked genes through H3K9me3 deposition in meiotic cells. MORC2 interacts with MORC1 and SETDB1 in testis. Conditional knockout mouse models (embryonic and postnatal germ cell-specific), bisulfite sequencing for DNA methylation, H3K9me3 ChIP, Co-immunoprecipitation (MORC2-MORC1, MORC2-SETDB1), RNA-seq, fertility assays Nucleic acids research High 41414675
2024 HUSH-MORC2-mediated silencing of LINE-1 retrotransposons is governed by DNA methylation hierarchy in human neural progenitor cells: L1s remain silenced by promoter DNA methylation when MORC2 or HUSH subunit TASOR is lost alone, but simultaneous loss of DNMT1 and MORC2 causes massive L1 transcript accumulation. Upon genome demethylation and L1 activation, MORC2 binding is specifically attracted to these activated L1s. CRISPR-mediated MORC2/TASOR/DNMT1 depletion in human neural progenitor cells, RNA-seq, MORC2 ChIP-seq, bisulfite sequencing, genetic epistasis analysis Nature communications High 39214989
2025 MORC2 undergoes biomolecular condensation to form dynamic nuclear assemblies required for its transcriptional repressor function. A crystal structure of coiled-coil 3 (CC3) identifies a dimeric scaffold serving as a structural hub. Multivalent interactions between an intrinsically disordered region (IDR) and a newly defined IDR-binding domain (IBD) drive condensation. DNA acts as a molecular scaffold triggering MORC2 condensation, which allosterically stimulates ATPase activity. Only dynamic condensates (not static aggregates or condensation-deficient mutants) can restore transcriptional regulation in MORC2-knockout cells. CMT2Z and SMA pathogenic variants perturb condensate material properties and enzymatic turnover. Crystal structure of CC3 at 3.1 Å, live-cell imaging of endogenous MORC2 condensates, FRAP, phase separation assays, 'killswitch' condensate disruption strategy, ATPase activity assays, transcriptional reporter assays in MORC2-KO cells, mutagenesis eLife High 42160388
2025 PGK1 functions as a protein kinase that phosphorylates MORC2 at serine 711 in response to ionizing radiation. Phosphorylated PGK1 (at S256 by CK2 following IR) interacts with MORC2. PGK1-dependent MORC2 phosphorylation at S711 enhances MORC2's DNA-dependent ATPase activity and facilitates chromatin remodeling and DNA repair. Disruption of PGK1-dependent MORC2 phosphorylation sensitizes PDAC cells to IR. In vitro kinase assay (PGK1 phosphorylating MORC2), Co-immunoprecipitation (PGK1-MORC2), ATPase activity assays, site-directed mutagenesis (S711), clonogenic survival assays, xenograft tumor model Cell death & disease Medium 41213904
2024 MORC2 binds to RBM39 (at its RRM1 domain) and promotes RBM39-mediated alternative splicing of CDK5RAP2 pre-mRNA, causing a switch from CDK5RAP2 L (long) to CDK5RAP2 S (short) isoform. CDK5RAP2 S specifically recruits PHD finger protein 8 to promote Slug transcription by removing repressive histone marks at the Slug promoter, driving EMT and metastasis in colorectal cancer. Co-immunoprecipitation (MORC2-RBM39), domain mapping (RRM1), alternative splicing RT-PCR, RIP assays, ChIP for histone marks at Slug promoter, invasion/metastasis assays, knockdown rescue experiments Cell death & disease Medium 39048555
2023 MORC2 recruits DNMT3A to the DAPK1 promoter to facilitate its hypermethylation, resulting in DAPK1 transcriptional silencing and promoting kidney renal clear cell carcinoma (KIRC) progression. Loss of NUDT21 causes 3'-UTR shortening (APA) that stabilizes MORC2 mRNA, enhancing this oncogenic axis. Co-immunoprecipitation (MORC2-DNMT3A), ChIP for DNMT3A and DNA methylation at DAPK1 promoter, bisulfite sequencing, NUDT21 knockdown, mRNA stability assays, xenograft models JCI insight Medium 37737260
2022 HSP90 N-terminal inhibitors (e.g., 17-AAG) disrupt MORC2 homodimer formation (independent of HSP90 itself), promoting MORC2 degradation via the chaperone-mediated autophagy (CMA) lysosomal pathway. The N-terminal homodimerization (but not ATP binding/hydrolysis) is critical for MORC2 protein stability. Immunoblotting, qRT-PCR, co-immunoprecipitation for dimerization, CMA pathway inhibition assays, lysosomal degradation assays, cell viability and metastasis assays Clinical and translational medicine Medium 35522895
2026 MORC2 mutations impair DNA repair by disrupting the interaction between MORC2 and PARP1, leading to reduced PARP1 activity and expression and diminished DNA repair protein recruitment. iPSC-derived motor neurons with MORC2 mutations (especially p.S87L) show apoptosis, DNA damage accumulation, shortened neurites, elevated axonal breakage, and axonal swellings. Inhibition of PAR degradation (with PDD) restores PAR levels, reduces DNA damage, and ameliorates axonal pathology. iPSC-derived motor neurons carrying MORC2 mutations, Co-immunoprecipitation (MORC2-PARP1), PARP1 activity assays, DNA repair protein recruitment assays, neurite morphology analysis, pharmacological rescue with PDD Pharmacological research Medium 41548771
2026 MORC2 cooperates with SETDB1 to deposit H3K9me3 repressive marks at transposable elements (TEs), silencing their expression and suppressing viral mimicry through inhibition of nucleic acid-sensing pathways and interferon responses. SETDB1 methylates MORC2 at K234 and K643 to enhance its stability, establishing a positive feedback loop reinforcing epigenetic silencing. MORC2 genetic ablation inhibits tumor growth in immunocompetent but not immunodeficient mice. Co-immunoprecipitation (MORC2-SETDB1), H3K9me3 ChIP-seq at TEs, methylation assays (SETDB1 methylating MORC2 at K234/K643), RNA-seq for TE transcripts, interferon response assays, MORC2 KO in immunocompetent vs. immunodeficient mice, ASO therapeutic experiments Molecular cancer Medium 42210236
2025 Reversible ATP-dependent dimerization of MORC2 is required for its accumulation over LINE-1 retrotransposons but not gene promoters. Engineered mutations of the MORC2 ATPase module disrupt L1 transcriptional control and cause hyper-repression of clustered ZNF genes in human pluripotent stem cells. Upon neural differentiation, these phenotypes persist due to defects in CpG methylation patterning over transcriptionally-active retrotransposons. ATPase module mutagenesis in human pluripotent stem cells, MORC2 ChIP-seq, RNA-seq, bisulfite sequencing for CpG methylation, neural differentiation assays bioRxivpreprint Medium 38895295

Source papers

Stage 0 corpus · 75 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2020 Acetylation of MORC2 by NAT10 regulates cell-cycle checkpoint control and resistance to DNA-damaging chemotherapy and radiotherapy in breast cancer. Nucleic acids research 160 32112098
2017 Hyperactivation of HUSH complex function by Charcot-Marie-Tooth disease mutation in MORC2. Nature genetics 131 28581500
2012 MORC2 signaling integrates phosphorylation-dependent, ATPase-coupled chromatin remodeling during the DNA damage response. Cell reports 121 23260667
2019 MORC2 regulates DNA damage response through a PARP1-dependent pathway. Nucleic acids research 87 31616951
2018 Cancer-Associated MORC2-Mutant M276I Regulates an hnRNPM-Mediated CD44 Splicing Switch to Promote Invasion and Metastasis in Triple-Negative Breast Cancer. Cancer research 85 30093560
2020 De Novo Variants in the ATPase Module of MORC2 Cause a Neurodevelopmental Disorder with Growth Retardation and Variable Craniofacial Dysmorphism. American journal of human genetics 83 32693025
2015 Mutations in the MORC2 gene cause axonal Charcot-Marie-Tooth disease. Brain : a journal of neurology 82 26497905
2022 O-GlcNAcylation of MORC2 at threonine 556 by OGT couples TGF-β signaling to breast cancer progression. Cell death and differentiation 74 34974534
2010 Involvement of histone deacetylation in MORC2-mediated down-regulation of carbonic anhydrase IX. Nucleic acids research 73 20110259
2018 Neuropathic MORC2 mutations perturb GHKL ATPase dimerization dynamics and epigenetic silencing by multiple structural mechanisms. Nature communications 71 29440755
2018 Epigenetic restriction of Hippo signaling by MORC2 underlies stemness of hepatocellular carcinoma cells. Cell death and differentiation 62 29555977
2013 Cytosolic functions of MORC2 in lipogenesis and adipogenesis. Biochimica et biophysica acta 59 24286864
2019 Stabilization of MORC2 by estrogen and antiestrogens through GPER1- PRKACA-CMA pathway contributes to estrogen-induced proliferation and endocrine resistance of breast cancer cells. Autophagy 55 32401166
2018 MORC2 promotes development of an aggressive colorectal cancer phenotype through inhibition of NDRG1. Cancer science 44 30407715
2016 MORC2 mutations cause axonal Charcot-Marie-Tooth disease with pyramidal signs. Annals of neurology 42 26659848
2015 By recruiting HDAC1, MORC2 suppresses p21 Waf1/Cip1 in gastric cancer. Oncotarget 40 26098774
2023 Dynamic SUMOylation of MORC2 orchestrates chromatin remodelling and DNA repair in response to DNA damage and drives chemoresistance in breast cancer. Theranostics 39 36793866
2015 PAK1-mediated MORC2 phosphorylation promotes gastric tumorigenesis. Oncotarget 39 25888627
2018 MORC2, a novel oncogene, is upregulated in liver cancer and contributes to proliferation, metastasis and chemoresistance. International journal of oncology 36 29620211
2018 MORC2 Enhances Tumor Growth by Promoting Angiogenesis and Tumor-Associated Macrophage Recruitment via Wnt/β-Catenin in Lung Cancer. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 34 30504718
2017 Clinical and mutational spectrum of Charcot-Marie-Tooth disease type 2Z caused by MORC2 variants in Japan. European journal of neurology 34 28771897
2010 Identification and expression analysis of a novel CW-type zinc finger protein MORC2 in cancer cells. Anatomical record (Hoboken, N.J. : 2007) 33 20225202
2017 Chromatin remodeling protein MORC2 promotes breast cancer invasion and metastasis through a PRD domain-mediated interaction with CTNND1. Oncotarget 31 29228664
2019 Dimerization of MORC2 through its C-terminal coiled-coil domain enhances chromatin dynamics and promotes DNA repair. Cell communication and signaling : CCS 30 31796101
2019 Characterization of molecular mechanisms underlying the axonal Charcot-Marie-Tooth neuropathy caused by MORC2 mutations. Human molecular genetics 29 30624633
2018 HSF1, in association with MORC2, downregulates ArgBP2 via the PRC2 family in gastric cancer cells. Biochimica et biophysica acta. Molecular basis of disease 29 29339121
2015 Microchidia protein 2, MORC2, downregulates the cytoskeleton adapter protein, ArgBP2, via histone methylation in gastric cancer cells. Biochemical and biophysical research communications 28 26476214
2019 MORC2 promotes cell growth and metastasis in human cholangiocarcinoma and is negatively regulated by miR-186-5p. Aging 27 31180332
2021 Circular RNA circDNM3OS Functions as a miR-145-5p Sponge to Accelerate Cholangiocarcinoma Growth and Glutamine Metabolism by Upregulating MORC2. OncoTargets and therapy 24 33628035
2019 MORC2 regulates C/EBPα-mediated cell differentiation via sumoylation. Cell death and differentiation 24 30644437
2021 The chromatin modifier MORC2 affects glucose metabolism by regulating the expression of lactate dehydrogenase A through a feed forward loop with c-Myc. FEBS letters 18 33626175
2023 Alternative polyadenylation reprogramming of MORC2 induced by NUDT21 loss promotes KIRC carcinogenesis. JCI insight 16 37737260
2023 The Spectrum of MORC2-Related Disorders: A Potential Link to Cockayne Syndrome. Pediatric neurology 14 36791574
2023 Oncogenic MORC2 in cancer development and beyond. Genes & diseases 14 37692502
2024 MORC2 regulates RBM39-mediated CDK5RAP2 alternative splicing to promote EMT and metastasis in colon cancer. Cell death & disease 13 39048555
2021 MORC2 Interactome: Its Involvement in Metabolism and Cancer. Biophysical reviews 13 34471435
2021 Charcot-Marie-Tooth disease due to MORC2 mutations in Spain. European journal of neurology 12 34189813
2022 HSP90 N-terminal inhibitors target oncoprotein MORC2 for autophagic degradation and suppress MORC2-driven breast cancer progression. Clinical and translational medicine 11 35522895
2024 DNA methylation governs the sensitivity of repeats to restriction by the HUSH-MORC2 corepressor. Nature communications 10 39214989
2022 MORC2/β-catenin signaling axis promotes proliferation and migration of breast cancer cells. Medical oncology (Northwood, London, England) 10 35727356
2021 Characterization of genotype-phenotype correlation with MORC2 mutated Axonal Charcot-Marie-Tooth disease in a cohort of Chinese patients. Orphanet journal of rare diseases 10 34059105
2023 MORC2 and MAX contributes to the expression of glycolytic enzymes, breast cancer cell proliferation and migration. Medical oncology (Northwood, London, England) 9 36802305
2022 Expanding the phenotypic variability of MORC2 gene mutations: From Charcot-Marie-Tooth disease to late-onset pure motor neuropathy. Human mutation 9 35904125
2022 Inhibition of MORC2 Mediates HDAC4 to Promote Cellular Senescence through p53/p21 Signaling Axis. Molecules (Basel, Switzerland) 9 36234785
2022 The TGF-β/SMAD Signaling Pathway Prevents Follicular Atresia by Upregulating MORC2. International journal of molecular sciences 7 36142569
2023 High Expression of MORC2 is Associated with Poor Clinical Outcomes and Immune Infiltrates in Colon Adenocarcinoma. International journal of general medicine 6 37850194
2025 Identification and characterization of a human MORC2 DNA binding region that is required for gene silencing. Nucleic acids research 5 39739841
2022 A Cockayne-like phenotype resulting from a de novo variant in MORC2: expanding the phenotype of MORC2-related disorders. Neurogenetics 5 35920923
2025 MORC2 is a phosphorylation-dependent DNA compaction machine. Nature communications 4 40593625
2023 High expression of MORC2 predicts worse neoadjuvant chemotherapy efficacy in triple negative breast cancer. Medicine 4 37352040
2026 Pleiotropic effects of MORC2 derive from its epigenetic signature. Brain : a journal of neurology 3 40302207
2024 The MORC2 p.S87L mutation reduces proliferation of pluripotent stem cells derived from a patient with the spinal muscular atrophy-like phenotype by inhibiting proliferation-related signaling pathways. Neural regeneration research 3 37488868
2023 Novel Insights into the Role of Chromatin Remodeler MORC2 in Cancer. Biomolecules 3 37892209
2021 Infantile-Onset Charcot-Marie-Tooth Disease With Pyramidal Features and White Matter Abnormalities Due to a De novo MORC2 Gene Variant: A Case Report and Brief Review of the Literature. Frontiers in neurology 3 34630290
2021 MORC2 gene de novo mutation leads to Charcot-Marie-Tooth disease type 2Z: A pediatric case report and literature review. Medicine 3 34664855
2024 Biological functions and molecular mechanisms of MORC2 in human diseases. Molecules and cells 2 39637946
2021 A recurrent MORC2 mutation causes Charcot-Marie-Tooth disease type 2Z. Journal of the peripheral nervous system : JPNS 2 33844363
2025 A select inhibitor of MORC2 encapsulated by chimeric membranecoated DNA nanocage target alleviation TNBC progression. Materials today. Bio 1 39906202
2025 Stage-dependent dual mechanisms of MORC2 in retrotransposon silencing and sex chromosome inactivation in germ cells. Nucleic acids research 1 41414675
2024 [Analysis of a child with DIGFAN syndrome due to variant of MORC2 gene]. Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics 1 38311566
2024 MORC2 phosphorylation fine tunes its DNA compaction activity. bioRxiv : the preprint server for biology 1 38979330
2024 Emerging roles of the chromatin remodeler MORC2 in cancer metabolism. Medical oncology (Northwood, London, England) 1 39117768
2024 Intermediate phenotype between CMT2Z and DIGFAN associated with a novel MORC2 variant: a case report. Human genome variation 1 39143067
2021 [A case of Charcot-Marie-Tooth disease type 2Z caused by MORC2 S87L mutation mimicking spinal muscular atrophy]. Rinsho shinkeigaku = Clinical neurology 1 33762496
2026 Impaired PARP1-dependent DNA repair in MORC2 mutations drives axonal degeneration in Charcot-Marie-Tooth disease subtype 2Z and spinal muscular atrophy-like neuromotor disorders. Pharmacological research 0 41548771
2026 MORC2 promotes acute myeloid leukemia by silencing LINE-1 retrotransposon. Functional & integrative genomics 0 41721893
2026 MORC2 Recruits Tumor-Associated Macrophages and Inhibits Pyroptosis Through Activating the Wnt/β-Catenin Pathway in Breast Cancer. Drug development research 0 42145133
2026 MORC2 mediates transcriptional regulation through liquid-liquid phase separation. eLife 0 42160388
2026 Targeting MORC2 activates transposable element-mediated viral mimicry and potentiates immune checkpoint blockade in triple-negative breast cancer. Molecular cancer 0 42210236
2025 MORC2 facilitates cholangiocarcinoma progression through cell cycle acceleration and immune microenvironment modification. Cellular and molecular biology (Noisy-le-Grand, France) 0 40285776
2025 The glycolytic enzyme PGK1 phosphorylates MORC2 to Confer radioresistance in pancreatic ductal adenocarcinoma. Cell death & disease 0 41213904
2025 The impact of MORC2 on glycolysis and the responsiveness of paclitaxel-resistant ovarian cancer cells. Cytotechnology 0 41216303
2024 A Novel Heterozygous De Novo MORC2 Missense Variant Causes an Early Onset and Severe Neurodevelopmental Disorder. Case reports in genetics 0 38204468
2024 Identification and characterization of a human MORC2 DNA binding region that is required for gene silencing. bioRxiv : the preprint server for biology 0 38895295
2024 Case Report: Charcot-marie-tooth disease caused by a de novo MORC2 gene mutation - novel insights into pathogenicity and treatment. Frontiers in genetics 0 39464795

Missed literature

Know a paper Affinage missed for MORC2? Flag it for the maintainers and the community.

No submissions yet.